Compare BLDR & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLDR | KOD |
|---|---|---|
| Founded | 1998 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | RETAIL: Building Materials | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 5.5B |
| IPO Year | 2005 | 2018 |
| Metric | BLDR | KOD |
|---|---|---|
| Price | $56.84 | $86.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 24 | 7 |
| Target Price | $71.36 | ★ $121.67 |
| AVG Volume (30 Days) | 2.2M | ★ 3.2M |
| Earning Date | 10-29-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $15,190,638,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.18 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $49.67 | $15.83 |
| 52 Week High | $131.50 | $104.00 |
| Indicator | BLDR | KOD |
|---|---|---|
| Relative Strength Index (RSI) | 51.20 | 59.00 |
| Support Level | $56.56 | $79.06 |
| Resistance Level | $61.82 | $103.63 |
| Average True Range (ATR) | 2.12 | 6.44 |
| MACD | 0.78 | -2.33 |
| Stochastic Oscillator | 90.94 | 33.91 |
Builders FirstSource Inc is a manufacturer and supplier of building materials. The company offers structural and related building products such as factory-built roof and floor trusses, wall panels and stairs, vinyl windows, custom millwork and trim, and engineered wood. The products can be designed for each home individually and are installed by Builders FirstSource. The company's construction-related services include professional installation, turn-key framing, and shell construction. Builders FirstSource's customers range from large production builders to small custom homebuilders.
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.